Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Modulation of gentamicin-induced acute kidney injury by myo-inositol oxygenase via the ROS/ALOX-12/12-HETE/GPR31 signaling pathway
Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
View: Text | PDF
Research Article Nephrology

Modulation of gentamicin-induced acute kidney injury by myo-inositol oxygenase via the ROS/ALOX-12/12-HETE/GPR31 signaling pathway

  • Text
  • PDF
Abstract

In this investigation, a potentially novel signaling pathway in gentamicin-induced acute kidney injury—worsened by overexpression of proximal tubular enzyme, myo-inositol oxygenase (MIOX)—was elucidated. WT, MIOX-transgenic (MIOX-Tg), and MIOX-KO mice were used. Gentamicin was administered to induce tubular injury. MIOX-Tg mice had severe tubular lesions associated with increased serum creatinine and proteinuria. Lesions were relatively mild, with no rise in serum creatinine and no albuminuria in MIOX-KO mice. Transfection of HK-2 cells with MIOX-pcDNA led to increased gentamicin-induced reactive oxygen species (ROS). Marked increase of ROS-mediated lipid hydroperoxidation was noted in MIOX-Tg mice, as assessed by 4-HNE staining. This was associated with increased expression of arachidonate 12-lipoxygenase (ALOX-12) and generation of 12-hydroxyeicosatetraenoic acid (12-HETE). In addition, notable monocyte/macrophage influx, upregulation of NF-κB and inflammatory cytokines, and apoptosis was observed in MIOX-Tg mice. Treatment of cells with ALOX-12 siRNA abolished gentamicin-mediated induction of cytokines and 12-HETE generation. HETE-12 treatment promoted this effect, along with upregulation of various signaling kinases and activation of GPCR31. Similarly, treatment of cells or mice with the ALOX-12 inhibitor ML355 attenuated inflammatory response, kinase signaling cascade, and albuminuria. Collectively, these studies highlight a potentially novel mechanism (i.e., the ROS/ALOX-12/12-HETE/GPR31 signaling axis) relevant to gentamicin-induced nephrotoxicity modulated by MIOX.

Authors

Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar

×

Figure 8

12-HETE promotes gentamicin induced inflammatory cytokines, activation of NF-κB, and modulation of MAPK cellular signaling kinases in HK-2 cells.

Options: View larger image (or click on image) Download as PowerPoint
12-HETE promotes gentamicin induced inflammatory cytokines, activation o...
Treatment of HK-2 cells with 12-HETE caused an increase in mRNA levels of TNF-α, IL-1β, and IL-6; the upregulation could be observed for up to 6 hours (A–C). The 12-HETE treatment also led to an increase in the phosphorylation of NF-κB subunit p65 and various signaling kinases of MAPK family, including JNK (Mr 46 kDa), p38 MAPK, and ERK (Mr 44/42 kDa) (G). These results indicate that proinflammatory effects of ALOX-12 are mediated via its substrate’s major metabolite, 12-HETE. Along these lines, the HK-2 cells treated with ML355, an inhibitor of ALOX-12, had a notable decrease in the expression of inflammatory cytokines (D–F, second column). Also, the cotreatment of cells with gentamicin and ML355 notably reduced the gentamicin-induced increased expression of inflammatory cytokines (D–F, fourth column). Along these lines, a notable decrease was observed in the expression of NF-κB subunit p65 and MAPKs, especially the phosphorylated form of the kinases, with the ML355 treatment (H). (n = 3 independent experiments with 2 duplicates each; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, compared with control PBS group; #P ≤ 0.01, compared with GEN group; 1-way ANOVA with Dunn’s multiple-comparison test).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts